about
TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations.Prognostic value of CD109+ circulating endothelial cells in recurrent glioblastomas treated with bevacizumab and irinotecan.Human glioblastoma stem-like cells accumulate protoporphyrin IX when subjected to exogenous 5-aminolaevulinic acid, rendering them sensitive to photodynamic treatment.A regulatory circuit of miR-125b/miR-20b and Wnt signalling controls glioblastoma phenotypes through FZD6-modulated pathways.MET inhibition overcomes radiation resistance of glioblastoma stem-like cells.Epigenetic Activation of WNT5A Drives Glioblastoma Stem Cell Differentiation and Invasive Growth.Extraneural metastases in glioblastoma patients: two cases with YKL-40-positive glioblastomas and a meta-analysis of the literature.Immunotherapy with dendritic cells loaded with glioblastoma stem cells: from preclinical to clinical studies.Identification and characterization of a new source of adult human neural progenitors.Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma.Sox2 is required to maintain cancer stem cells in a mouse model of high-grade oligodendroglioma.Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O6-Methylguanine-DNAAccuracy of 2-hydroxyglutarate quantification by short-echo proton-MRS at 3 T: a phantom study.EGFR amplified and overexpressing glioblastomas and association with better response to adjuvant metronomic temozolomide.Survival gain in glioblastoma patients treated with dendritic cell immunotherapy is associated with increased NK but not CD8+ T cell activation in the presence of adjuvant temozolomide.Erratum to: Radiosurgery reirradiation for high-grade glioma recurrence: a retrospective analysis.Constitutive and TNFα-inducible expression of chondroitin sulfate proteoglycan 4 in glioblastoma and neurospheres: Implications for CAR-T cell therapyThe molecular landscape of glioma in patients with Neurofibromatosis 1NG2/CSPG4 in glioblastoma: about flexibility
P50
Q34499685-D838EFC7-42CE-407D-8335-F577CD7F27B0Q34999120-06257FC6-BD11-44BA-9B3A-BA8D2D30239EQ36121449-8962964E-5D7F-4DBF-967F-A6D2FD5F650AQ37329811-F4831EB4-A9EE-4F59-A371-6FD44BAD43F8Q37458626-CAED83EC-E0AC-4D23-950A-8BD2F8354A5FQ37658825-8FB33D40-AC06-459B-91CC-425E8560D604Q38554801-9226A704-AFE9-469F-898D-28E1FD235F91Q38588141-98178FB1-8F61-4397-9DA5-E7A0ED2D301EQ38630702-6BD85FC1-0BF7-4B6A-BA5A-09FDCD03CAA2Q38890122-6D1B24B7-CB5F-44A8-9E2C-8B6DA5ADBD45Q39018292-8AFD4BA9-9993-4D4F-ACBE-FAA5CE7DFB3EQ40441135-DC4E3577-FC2A-4792-9447-BFAC356681FEQ45756967-8285B19D-9488-4C58-92BE-3D6BBB723073Q45873617-4906BB29-042F-4460-8243-9491C1FFE434Q52597547-89F4BA28-17F9-4EE6-9903-4623D6443747Q55460080-E913D16B-D222-4103-82F1-E21D5D7EBBE1Q57946555-6E06FDDA-38BC-4D85-9A34-DE7E00A6579EQ90371443-2EDD7661-5531-4706-8E37-1F0F0BA2A4DFQ92662660-5DBB2ED6-A8D3-4B33-AB3D-B1CC4411E46A
P50
description
researcher
@en
name
Gaetano Finocchiaro
@en
type
label
Gaetano Finocchiaro
@en
prefLabel
Gaetano Finocchiaro
@en
P31
P496
0000-0003-3583-4040